aortic stenosis

TAVR: Regression of Left Ventricular Hypertrophy Decreases Re-hospitalization

Original title:&nbsp;Early Regression of Severe Left Ventricular Hypertrophy After Transcatheter Aortic Valve Replacement Is Associated with Decreased Hospitalization.&nbsp;Reference:&nbsp;Brian Lindman, et al. JACC Cardiovasc Interv 2014;7:662-73. &nbsp; Left ventricular hypertrophy, defined by the increase of left ventricular mass, has long been associated to increased morbi-mortality in the context of different heart conditions. LV hypertrophy regression might<a href="https://solaci.org/en/2014/08/05/n-4642/" title="Read more" >...</a>

Prognostic factors for early mortality in patients undergoing TAVI; Individual risk calculation using a simple score: Derivative analysis from FRANCE II Registry.

Original title:&nbsp;Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple escore.&nbsp;Reference:&nbsp;Heart. 2014 Apr 16. doi: 10.1136/heartjnl-2013-305314. Epub ahead of print. &nbsp; The decision to perform an intervention in symptomatic aortic stenosis must balance surgery or transcatheter aortic valve implantation (TAVI) risk. Factors associated with early mortality after TAVI<a href="https://solaci.org/en/2014/04/30/n-4425/" title="Read more" >...</a>

Low flow impact on outcomes following TAVI should be taken into account

Original title:&nbsp;Impact of Low Flow on the Outcome of High-Risk Patients Undergoing Transcatheter Aortic Valve Replacement.&nbsp;Reference:&nbsp;Florent Le Ven, et al. J Am Coll Cardiol 62;9:792-788 A study of low flow (SVi &lt;35ml/m2) in the context of severe aortic stenosis has shown it is a predictor of worse outcomes after surgery, even though evolution with medical<a href="https://solaci.org/en/2013/08/26/n-3550/" title="Read more" >...</a>

Carotid angioplasty prior to central venous catheter. The best option to solve combined problems.

Original title:&nbsp;A Direct Comparison of Early and Late Outcomes with Three Approaches to Carotid Revascularization and Open Heart Surgery.&nbsp;Reference:&nbsp;Mehdi H. Shishehbor et al. J Am Coll Cardiol, article in press. &nbsp; The prevalence of severe carotid stenosis (&gt; 80%) in patients planning to have a Central Venous Catheter (CVC) is estimated at between 6 and<a href="https://solaci.org/en/2013/08/08/n-3501/" title="Read more" >...</a>

What is the contrast media dosing that predicts acute kidney injury after TAVI?

Original title:&nbsp;Renal Function-Based Contrast Dosing Predicts Acute Kidney Following Trancatheter Aortic Valve Implantation&nbsp;Reference:&nbsp;Masanori Yamamoto, et al. J Am Coll Cardiol Intv 2013;6:479&ndash;86. Acute kidney injury (AKI) presents in 10 to 30% of patients undergoing TAVI; it is associated to the increase of morbidity and mortality and it prolongues hospitalization. This study included 415 patients with<a href="https://solaci.org/en/2013/06/05/n-2668/" title="Read more" >...</a>

Post TAVI Hypertension is a predictor of better evolution

Original title:&nbsp;Post-Procedural Hypertension Following Transcatheter Aortic Valve Implantation Incidence and Clinical Significance.&nbsp;Reference:&nbsp;Gidon Y. Perlman et al. J Am Coll Cardiol Intv 2013. Article in press. Pre-procedural hypertension (HTN) is a risk factor and a predictor of increased mortality after surgical aortic valve replacement (AVR). The disappearance of the pressure gradient across the aortic valve following<a href="https://solaci.org/en/2013/05/02/n-2689/" title="Read more" >...</a>

Valve-in-Valve Implantation Is Possible

Original title:&nbsp;5 Years Experience With Trancatheter Tranaspical Mitral Valve &ndash;in Valve Implantation for Bioprosthetic Valve Dysfunction&nbsp;Reference:&nbsp;Anson Cheung et al. J Am Coll Cardiol 2013;61:1759&ndash;66. Percutaneous valves development, first aortic and now mitral, has brought an opportunity to improve life quality and extend life for high risk non-surgical patients. 23 patients received transapical implantation in mitral<a href="https://solaci.org/en/2013/04/29/n-2913/" title="Read more" >...</a>

Favorable outcomes at 5 years post TAVI.

Original title:&nbsp;5-Year Outcome After Aortic Valve Implantation&nbsp;Reference:&nbsp;Stefan Toggweiler, et al. J Am Coll Cardiol 2013;61:413&ndash;9 Percutaneous aortic valve implantation (TAVI) is now a valid strategy as we know its short and medium term evolution but we do not have enough information available about the long term.&nbsp; The aim of this study was to analyze the<a href="https://solaci.org/en/2013/01/28/n-3256/" title="Read more" >...</a>

The largest published series of valve-in-valve with Core Valve, (Medtronic).

Original title: Valve-in-Valve Implantation of Medtronic CoreValve Prosthesis in Patients with Failing Bioprosthetic Aortic Valves. Reference: Axel Linke el al. Circ Cardiovasc Interv. 2012;5:689-697. This study evaluates the safety, feasibility and results of Core Valve implants on patients with bioprostheses dysfunctional by stenosis, insufficiency or a combination of both. Biological prostheses are preferred over mechanical ones for patients<a href="https://solaci.org/en/2012/11/02/the-largest-published-series-of-valve-in-valve-with-core-valve-medtronic/" title="Read more" >...</a>

Vascular complications after valvular replacement using catheter: PARTNER trial findings

Reference:&nbsp;G&eacute;n&eacute;reux, et al, for the PARTNER Trial Investigators. JACC 2012; 60 (12):1043-62 Original title: Vascular complications after Transcatheter Aortic Valve Replacement: Insights From the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial The purpose of the study was to investigate the incidence, predictors and vascular complications impact after catheter aortic valve implantation (TAVI) in the PARTNER<a href="https://solaci.org/en/2012/10/01/n-3886/" title="Read more" >...</a>

Top